<DOC>
	<DOCNO>NCT00001587</DOCNO>
	<brief_summary>Patients unresectable primary metastatic cancer confine liver undergo 1 hour hyperthermic isolate hepatic perfusion ( IHP ) via portal vein hepatic artery escalate dose melphalan . Patients eligible protocol non-colorectal histology colorectal cancer previously treat intra-arterial FUDR . Hepatic systemic toxicity , response treatment , duration response , survival follow .</brief_summary>
	<brief_title>A Phase I Study Isolated Hepatic Portal Arterial Perfusion ( IHP ) With Escalating Dose Melphalan Primary Metastatic Unresectable Cancers Liver</brief_title>
	<detailed_description>Patients unresectable primary metastatic cancer confine liver undergo 1 hour hyperthermic isolate hepatic perfusion ( IHP ) via portal vein hepatic artery escalate dose melphalan . Patients eligible protocol non-colorectal histology colorectal cancer previously treat intra-arterial FUDR . Hepatic systemic toxicity , response treatment , duration response , survival follow .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Histologically cytologically proven measurable primary metastatic noncolorectal cancer limit parenchyma liver evidence unresectable extrahepatic disease preoperative radiological study . Limited resectable extrahepatic disease acceptable . Patients colorectal cancer previously treat intrahepatic arterial infusional therapy use FUDR , aberrant arterial anatomy infusional therapy possible , limited extrahepatic disease regional therapy indicate eligible protocol . Patients must chemotherapy , radiotherapy , biologic therapy malignancy month prior liver perfusion must recover side effect . Patients must ECOG performance standard 0 , 1 2 day prior treatment . Patients must adequate hepatic function evidence bilirubin le 2.0 PT PTT within 12 second upper normal limit . No patient biopsy proven cirrhosis evidence significant portal hypertension history , endoscopy , radiologic study include . No patient history congestive heart failure LVEF equal less 40 % include . No patient COPD chronic pulmonary disease PFT 's less 50 % predict age include . Patients must 18 year age old . Patients must platelet count great 100,000 , HCT great 27.0 , white blood count great 3000/ microgram , creatinine le equal 1.5 creatinine clearance great 60 ml/min . No pregnant patient nurse mother eligible . Patients must take immunosuppressive drug chronic anticoagulation . Patients must active infection . Patients severe allergic reaction iodine contrast control premedication antihistamine steroid eligible hepatic angiogram need procedure . Patients must HIV disease . Patients must aware neoplastic nature his/her illness , experimental nature therapy , alternative treatment , potential benefit , risk . The patient must willing sign inform consent . Patients must history veno occlusive disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Hyperthermia</keyword>
	<keyword>Metastases</keyword>
	<keyword>Organ Perfusion</keyword>
	<keyword>Regional Therapy</keyword>
</DOC>